Trial Profile
Assessment of durable remission and relapse-free survival of humanized CD19-targeted chimeric antigen receptor (CAR)-modified T cells (CTL119) in CAR-naive and CAR-exposed children and young adults with relapsed/refractory acute lymphoblastic leukemia: A phase I study
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 22 Dec 2017
Price :
$35
*
At a glance
- Drugs CTL 119 (Primary)
- Indications B-cell leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; Therapeutic Use
- 22 Dec 2017 New trial record
- 12 Dec 2017 Results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology